Evidence map›Paper›PMID 42496818›Full record

ArticleJournal of endocrinological investigation2026

Osteoprotegerin is strongly associated with calcium and magnesium in seminal fluid but not affected by denosumab.

Sam Kafai Yahyavi, Mads Joon Jorsal, Emil Brink Wriedt, Niels Jørgensen, Anders Juul, Rune Holt, Martin Blomberg Jensen

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03030196 (Denosumab and Male Infertility), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03030196 phase2completednot on this map

Denosumab and Male Infertility: a Randomized Controlled Double-blinded Intervention Study

TypeinterventionalSponsorMartin Blomberg JensenRan2017 to 2023Enrolled95ConditionsInfertility, MaleArmsDenosumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sam Kafai YahyaviDivision of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Mads Joon JorsalDivision of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Emil Brink WriedtDivision of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Niels JørgensenDepartment of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Anders JuulDepartment of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Rune HoltDivision of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
Martin Blomberg JensenDivision of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark. martin.blomberg.jensen@regionh.dk.ORCID http://orcid.org/0000-0003-3800-4253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWhile the effect of the RANKL-inhibitor denosumab on serum minerals is well-documented, its impact on seminal fluid minerals is poorly understood. This study examines the correlation between the high levels of soluble-RANKL, osteoprotegerin (OPG), and minerals in seminal fluid and whether this can be influenced by denosumab.

methodsTwo cohorts comprised this study: 100 young men from the general Danish population with no reported fertility issues, and 91 infertile men who were treated with a single dose of denosumab (60 mg), or placebo in a randomized controlled trial assessing the effect on semen quality. Each man underwent a physical examination and semen analysis, including analysis of soluble RANKL, OPG, calcium, magnesium, and phosphate in the seminal fluid.

resultsIn both men from the general population and infertile men, seminal OPG concentrations were positively correlated with seminal calcium (r

conclusionA strong correlation between OPG and minerals in seminal fluids from both normal and infertile men suggests that the release of these factors by the prostate or seminal vesicle is regulated by the same factors, but cannot be modified by a short-term systemic RANKL inhibition with denosumab. CLINICAL

trial registrationClinicalTrials.gov NCT03030196. Registered January 24, 2017.

Indexed as

InfertilityMineralsRandomized controlled trialSeminal OPGsRANKL

Identifiers

PMID42496818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.